Skip to search formSkip to main content

GSK2251052

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The emergence of multidrug-resistant (MDR) Gram-negative bacilli is a major concern in the treatment of nosocomial infections… Expand
Is this relevant?
2016
2016
GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II… Expand
Is this relevant?
2015
2015
GSK2251052, a novel leucyl-tRNA synthetase (LeuRS) inhibitor, was in development for the treatment of infections caused by… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
The plasma and intrapulmonary pharmacokinetics (PK) of intravenous (i.v.) GSK2251052, a novel boron-containing antimicrobial… Expand
Is this relevant?
2013
2013
GSK2251052 is a boron-containing antimicrobial agent in clinical development for the treatment of serious Gram-negative bacterial… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2013
2013
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
Is this relevant?
2013
2013
We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical… Expand
Is this relevant?
2013
2013
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2013
2013
10 Running Title: Pulmonary and Plasma PK of GSK2251052 11 12 13 # Corresponding author: Parul Patel, Pharm.D. 14 GlaxoSmithKline… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?